Asia
Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.
Astellas Pharma is building on a 2019 collaborative relationship and snapping up California-based iota Biosciences and that company’s bioelectronics technology in order to accelerate its Rx+ business.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Find out which life sciences companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Takeda has entered into a five-year agreement with Accenture and Amazon Web Services (AWS) to support the Tokyo-based pharmaceutical company in moving 80% of its applications to the “cloud” and modernizing the company’s research tools.
The Beijing-based biotech will use the Series B funds to further their hematopoietic disease and cancer therapies pipeline and expand team.
Innovent and Lilly expect Halpryza to be a high quality and slightly more affordable rituximab injection for a market experiencing serious needs.
It was a moderately busy week for clinical trial news. Here’s a look.
The investigational drug, ARO-AAT, is a potential first-in-class treatment that reduces the generation of mutant alpha-1 antitrypsin protein (Z-AAT), the primary contributor to liver disease progression in patients with AATLD.
PRESS RELEASES